Suchergebnisse - "Cortes, Javier"

PubPharm (706)

1

Preventing alpelisib-related hyperglycaemia in HR+/HER2-/PIK3CA-mutated advanced breast cancer using metformin (METALLICA) : a multicentre, open-label, single-arm, phase 2 trial

enthalten in: EClinicalMedicine | 2024

von Llombart-Cussac, A. | Pérez-Garcia, J. | Ruiz Borrego, M. | +25

2

Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer : exploratory analysis from KEYNOTE-119

enthalten in: The journal of pathology. Clinical research | 2024

von Cortes, J. | Winer, E. | Lipatov, O. | +18

3

Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer : RESPONSE, a substudy of the randomized PHERGain trial

enthalten in: European journal of nuclear medicine and molecular imaging | 2024

von Llombart-Cussac, A. | Prat, A. | Pérez-García, J. | +18

4

Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial

enthalten in: Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2024

von Gebhart, G. | Keyaerts, M. | Guiot, T. | +23

5

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain) : a randomised, open-label, phase 2 trial

enthalten in: Lancet (London, England) | 2024

von Pérez-García, J. | Cortés, J. | Ruiz-Borrego, M. | +27

6

Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer

enthalten in: International journal of molecular sciences | 2024

von Franco-Mateos, E. | Souza-Egipsy, V. | García-Estévez, L. | +11

7

A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative)

enthalten in: Future oncology (London, England) | 2024

von Rugo, H. | Bardia, A. | Marmé, F. | +4

8

Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer : Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Rastogi, P. | O'Shaughnessy, J. | Martin, M. | +20

9

Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer : An Expert Consensus on Open Issues for Future Research

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Conforti, F. | Pala, L. | De Pas, T. | +13

10

Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab

enthalten in: Breast cancer research and treatment | 2024

von Gion, M. | García-Mosquera, J. | Pérez-García, J. | +12

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[71]